Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5474-5483

  Rugo, Hope S ^a   Herbst, Roy S ^a   Liu, Glenn ^a   Park, John W ^a   Kies, Merrill S ^a   Steinfeldt, Heidi M ^a   Pithavala, Yazdi K ^a   Reich, Steven D ^a   Freddo, James L ^a   Wilding, George ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; AXITINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RABEPRAZOLE; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER FATIGUE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOOD DRUG INTERACTION; GLOSSODYNIA; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SEIZURE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; VOICE CHANGE; VOMITING; AREA UNDER THE CURVE; BLOOD; DRUG ADMINISTRATION; DRUG INTERACTION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 24944453855     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.192     Document Type: Article

References (45)

1. Folkman J: Fundamental concepts of the angiogenic process. Curr Mol Med 3:643-651, 2003
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
3. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18, 2002
4. Folkman J, Watson K, Ingber D, et al: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989
5. Huss WJ, Hanrahan CF, Barrios RJ, et al: Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 61:2736-2743, 2001
6. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:765-782, 1995
7. Hayes AJ, Li LY, Lippman ME: Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment. BMJ 318: 853-856, 1999
8. Folkman J, D'Amore PA: Blood vessel formation: What is its molecular basis? Cell 87:1153-1155, 1996
9. Senger DR: Molecular framework for angiogenesis: A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol 149:1-7, 1996
10. Shinkaruk S, Bayle M, Lain G, et al: Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anti-Canc Agents 3:95-117, 2003
11. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611, 2004
12. Fontanini G, Vignati S, Boldrini L, et al: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3:861-865, 1997
13. Takahashi R, Tanaka S, Kitadai Y, et al: Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64:266-274, 2003
14. Bellamy WT, Richter L, Frutiger Y, et al: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733, 1999
15. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893, 2002
16. Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: A prospective study. J Clin Oncol 20:1775-1785, 2002
17. Folkman J: Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2:S127-S133, 2003
18. Glade-Bender J, Kandel JJ, Yamashiro DJ: VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3:263-276, 2003
19. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
20. Vulfovich M, Saba N: Molecular biological design of novel antineoplastic therapies. Expert Opin Investig Drugs 13:577-607, 2004
21. Inai T, Mancuso M, Hashizume H, et al: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35-52, 2004
22. Liu G, Rugo HS, Wilding G, et al: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol (in press)
23. DeGeorge J, Ahn C-H, Andres P, et al: Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41:173-185, 1998
24. Cancer Therapy Evaluation Program: Common Terminology Criteria, Version 2.0, Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health, 1998, Department of Health and Human Services, April 30, 1999
25. Therasse P, Arbuck SG, Eisenhower EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
26. Rosen L, Mulay M, Long J, et al: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 765)
27. Stopeck A, Sheldon M, Vahedian M, et al: Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798-2805, 2002
28. Thomas AL, Morgan B, Drevs J, et al: Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 30:32-38, 2003
29. O'Farrell AM, Foran JM, Fiedler W, et al: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9:5465-5476, 2003
30. George D, Michaelson D, Oh WK, et al: Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22:385, 2003 (abstr 1548)
31. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
32. Rugo HS: Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 9:43-49, 2004 (suppl 1)
33. Veronese ML, Flaherty R, Townsend A, et al: Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. Proc Am Soc Clin Oncol 22:135s, 2004 (abstr 2035)
34. Bouloumie A, Schini-Kerth VB, Busse R: Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 41:773-780, 1999
35. Kroll J, Waltenberger J: A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun 265:636-639, 1999
36. Shiojima I, Walsh K: Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90:1243-1250, 2002
37. Wickman G, Hallin M, Salansky KA, et al: Further characterization of the potent VEGF/ PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Cancer Res 44:865, 2003 (abstr 3780)
38. Sun L, McMahon G: Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov Today 5:344-353, 2000
39. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739, 2002
40. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784-793, 2004
41. Bergers G, Javaherian K, Lo KM, et al: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999
42. Mundhenke C, Thomas JP, Wilding G, et al: Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin. Clin Cancer Res 7:3366-3374, 2001
43. O'Farrell AM, Yuen HA, Smolich B, et al: Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 28:679-689, 2004
44. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
45. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-6, 2004